The Question That Doesn't Seem to Go Away: Cancer Risk of Anti-TNF Therapy
- PMID: 33595781
- DOI: 10.1007/s10620-021-06883-w
The Question That Doesn't Seem to Go Away: Cancer Risk of Anti-TNF Therapy
Comment on
-
Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series.Dig Dis Sci. 2022 Jan;67(1):252-258. doi: 10.1007/s10620-021-06884-9. Epub 2021 Feb 17. Dig Dis Sci. 2022. PMID: 33595782
References
-
- Olen O, Askling J, Sachs MC et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964–2014. BMJ 2017;358:j3951 - DOI
-
- Kjaergaard VS, Jensen CB, Elmahdi R, Burisch J, Allin KH, Jess T. Cancer risk in pediatric-onset inflammatory bowel disease: a population-based Danish cohort study. Gastroenterology 2020;159:1609–1611 - DOI
-
- Kotlyar DS, Lewis JD, Beaugerie L et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015;13:847–858 (quiz e48-50). - DOI
-
- Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361–371 - DOI
-
- Nyboe Andersen N, Pasternak B, Basit S et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014;311:2406–2413 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical